4results about "Endopeptidase" patented technology

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

Use of a fructose disaccharide or fructooligosaccharide, for increasing protein production in Bifidobacterium longum subsp longum.

This disclosure provides alpha-1 antitrypsin (AAT) polypeptides as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, methods for producing the AAT polypeptide, and methods for using the AAT polypeptide in therapy.

To provide novel therapeutic agents to treat or ameliorate the symptoms of skin diseases, in particular, Netherton Syndrome.SOLUTION: A composition for the treatment of a skin disease comprises a microbe genetically modified to express and provide one or more LEKTI protein domains on the skin of a mammal, where the LEKTI protein domains are effective to penetrate one or more layers of the mammal's skin and effective to inhibit serine protease activity of at least one serine protease in or on the mammal's skin.SELECTED DRAWING: None